TAMPA, Fla., Nov. 28, 2025 (GLOBE NEWSWIRE) -- FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) ("FLUENT" or the "Company"), a vertically-integrated, multi-state cannabis company, today announced its financial and operating results for the third quarter ended September 30, 2025. Unless otherwise indicated, all financial results are presented in U.S. dollars.
Management Commentary
"During the third quarter, we continued to execute on our strategic priorities with a clear focus on reversing the declining margin profile and enhancing operational efficiency across our footprint ahead of our new indoor capacity hitting retail shelves in the fourth quarter," said Dave Vautrin, Interim CEO of FLUENT. "While consolidated revenue was relatively consistent year-over-year, we recognized pressure on gross margins driven by correcting extraction inefficiencies and a shifting product mix in Florida. We have already taken decisive actions to address these challenges, including optimizing our retail portfolio, improving distillate yields, accelerating product innovation, and bringing key indoor production facilities fully online."
Vautrin continued, "We have also made disciplined investments during the current quarter in markets where we expect meaningful margin contribution. In Florida, we operationalized our large-scale Rosa indoor cultivation facility in November, nearly doubling our premium flower capacity. The Rosa facility is ramping up as planned and is now delivering true premium-quality flower and measurable improvements in yield, which we expect will support our objectives of achieving stronger margins through larger capture of the Florida premium market opportunity heading into 2026. In New York, we have operationalized our large-scale Buffalo premium indoor cultivation facility in Q4 2025 and are now preparing for the launch of premium SKUs from Connected and Alien Labs, which we believe will energize our efforts to improve our wholesale revenue and margin contribution. Across all markets, our near-term focus remains on optimizing operational excellence, capital efficiency, and driving sustainable margin expansion as we position FLUENT for long-term value creation."
Q3 2025 Financial Highlights (vs. Q3 2024)
- Revenue: $26.0 million compared to $26.1 million in Q3 2024.
- Florida revenue: $21.6 million compared to $22.0 million in Q3 2024, reflecting pricing pressures.
- Gross profit before fair value adjustments1- $8.0 million (31% of revenue) compared to $14.3 million (54.6% of revenue) in Q3 2024.
- Adjusted EBITDA2- $2.8 million compared to $7.5 million in Q3 2024, primarily due to lower revenue and reduced margins.
- Cash flow from operations: Cash used in operations of $.8 million, compared to cash provided by operations of $9.5 million in Q3 2024.
- Balance sheet: On September 30, 2025, the Company had cash and cash equivalents of approximately $15.1 million and total debt outstanding of $72.2 million, compared to $8.9 million of cash and cash equivalents and $71.4 million in total debt outstanding on September 30, 2024. Common shares outstanding on an as-converted basis were approximately 714 million in Q3 2025 compared to 342 million common shares outstanding on an as-converted basis in Q3 2024.
Recent Operational Highlights
Company Footprint:
- FLUENT currently operates at a total of 37 retail locations and 8 production facilities across its key markets of Florida, New York, Pennsylvania, and Texas.
Florida:
- Closed five of the lowest-performing dispensaries and opened a new location in Brandon, bringing total number of active stores to 31.
- Anticipated new dispensaries in Orlando Sand Lake (expected to open in Q4 2025) and Palm Bay (expected to open in Q1 2026) to grow statewide reach to 33 locations.
- Relaunched physician and community outreach programs to strengthen patient engagement.
- Completed first harvests at Rosa indoor production facility. Focused on continued scaling up of canopy, improving consistency, yield, and throughput.
- The Company anticipates improved distillate yields will contribute to margin recovery in Q4 2025.
- Launched Bag-O 7g ground flower, now available statewide.
New York:
- Buffalo production facility nearing full operational status; initial retail and wholesale launch of Connected and Alien Labs SKUs expected this December, with 9 Alien Labs and 11 Connected strains in the first wave.
- ENTOURAGE, the Company's wholesale division, continues to expand distribution and revenue statewide.
- Rebranding completed for all three co-located dispensaries in Manhattan, White Plains, and Kingston.
- Closed Syracuse medical-only dispensary, planning a new medical-only location in 2026.
Texas:
- Houston Education and Pick-Up Center expected to open in December 2025.
- Production underway for new Rick Simpson Oil (RSO) and distillate syringe products, with additional SKUs in active R&D.
Pennsylvania:
- The Company currently operates three dispensaries in south-central Pennsylvania (Hanover, Mechanicsburg and Annville).
- The Company continues to evaluate regulatory developments to assess future growth opportunities.
_______________________
1 Gross profit before fair value adjustments is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates gross profit before fair value adjustments from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations.
2 Adjusted EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates Adjusted EBITDA as EBITDA (being calculated as the net income (loss), plus (minus) interest expense (income) and finance transactions costs, plus taxes, plus depreciation and amortization) plus (minus) the changes in fair value of biological assets, plus (minus) the changes in fair market value of derivatives, plus (minus) certain one-time non-operating expenses, as determined by management.
Regulatory Progress
The United States federal government recently announced plans to close what proponents call the hemp-derived THC loophole created under the 2018 Farm Bill that allowed hemp-derived products containing tetrahydrocannabinol, or THC, to be sold. Management views this as a potentially meaningful tailwind for regulated operators that is expected to curb the widespread availability of intoxicating hemp products that currently operate outside the licensed cannabis framework.
The impact is expected to be particularly significant in Florida and Texas:
- Florida: Unregulated hemp-derived THC has impacted pricing and category mix in the Florida market. A federal crackdown is expected to reduce illicit competition and support margin recovery in the regulated medical market. Currently, the Florida Department of Agriculture and Consumer Services estimates that there are more than 9,500 hemp retailers in the state3, while Florida's office of Medical Marijuana Use reports 734 licensed dispensaries4, meaning for every one legal licensed dispensary there are approximately 12 resellers of hemp derived cannabis in Florida.
- Texas: With more than 8,000 hemp resale licenses in Texas5, the state has become a major market for hemp-derived THC products. Management of the Company believes that the recent regulatory changes in Texas and the recently announced U.S. federal action are expected to materially rebalance the competitive landscape in Texas and enhance long-term economics for compliant medical operators in the state.
FLUENT anticipates these regulatory developments may pave a path forward for a more stable, regulated market environment, which will in turn support the Company's focus on improving margins across its portfolio.
Conference Call
The Company will not host an earnings call for the quarter.
_______________________
3 Source: https://www.miamiherald.com/news/politics-government/state-politics/article294313734.html
4Source: https://knowthefactsmmj.com/about/weekly-updates/
5Source: https://www.bakerinstitute.org/research/texas-lawmakers-have-chance-get-hemp-regulation-right
About FLUENT Corp.
FLUENT, a national cannabis consumer packaged goods company and retailer, is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by FLUENT's unrelenting commitment to operational excellence in cultivation, production, distribution, and retail experience. FLUENT produces an assortment of cannabis products under a diverse portfolio of brands including MOODS, Knack, Wandr, Bag-O and Hyer Kind. FLUENT operates in Florida, New York, Pennsylvania, and Texas.
Headquartered in Tampa, Florida, FLUENT employs 700 employees across 8 cultivation and manufacturing facilities, 37 active retail locations and a wholesale division which trades under ENTOURAGE servicing third party retailers in New York. For more information on the Company's wholesale division ENTOURAGE, please visit https://entouragewholesale.com/.
FLUENT's common shares trade on the Canadian Securities Exchange under the symbol "FNT.U" and on the OTCQB Venture Market under the symbol "CNTMF". For more information about the Company, please visit www.getFLUENT.com and investors.getFLUENT.com/.
Forward-Looking Information
Certain information in this news release may constitute forward-looking information within the meaning of applicable securities laws and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved" or similar expressions and includes, but is not limited to, statements with respect to the Company's focus on reversing declining margins and enhancing operational efficiency across the Company's footprint; expectations regarding the Company's new indoor capacity; expectations regarding stronger margins, wholesale revenue and margin contribution; the timing, occurrence and expectations regarding future product offerings, dispensaries, medical-only locations and pick-up centers; the Company's ongoing evaluation of regulatory developments and the timing, occurrence expectations of such developments; the anticipated impacts of recent regulatory changes in Florida and Texas; and the Company's expectations regarding operational excellence, capital efficiency, driving sustainable margin expansion and long-term value creation. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent the Company's expectations, estimates, and projections regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control.
Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the Company's ability to execute its go-forward strategy; stock market volatility; changes in the business activities, focus and plans of the Company and the timing associated therewith; the timing of any changes to federal laws in the U.S. to allow for the general cultivation, distribution, and possession of cannabis; regulatory and licensing risks; changes in cannabis industry growth and trends; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation, including the Company's interpretation of such regulation; public opinion and perception of the cannabis industry; and the risk factors described in the public filings of the Company filed with Canadian securities regulators and available under the Company's SEDAR+ profile at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
The Company, through several of its subsidiaries, is directly involved in the manufacture, possession, use, sale, and distribution of cannabis in the adult-use and medical cannabis marketplace in the United States. Local state laws where the Company operates permit such activities however, investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the United States Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable United States federal money laundering legislation.
While the approach to enforcement of such laws by the federal government in the United States has trended toward nonenforcement against individuals and businesses that comply with adult-use and medical cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under United States federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. The enforcement of federal laws in the United States is a significant risk to the business of the Company and any proceedings brought against the Company thereunder may adversely affect operations and financial performance.
The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
For further information visit: https://getfluent.com/ and https://investors.getFLUENT.com/
Investor Relations Contact:
investors@getFLUENT.com
Media Contact:
press@getFLUENT.com
Officer Contact:
Matt Mundy, Chief Legal Officer
(850) 972-8077
| FLUENT CORP. | |||||||
| CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | |||||||
| As of September 30, 2025 and December 31, 2024 | |||||||
| (USD '000) | |||||||
| September 30, | December 31, | ||||||
| 2025 | 2024 | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents (includes $4,500 of restricted cash) | - | 15,112 | - | 40,106 | |||
| Accounts receivable | 862 | 422 | |||||
| Biological assets | 3,112 | 3,162 | |||||
| Inventory, net | 15,795 | 15,155 | |||||
| Prepaid expenses and other current assets | 2,826 | 2,587 | |||||
| Total current assets | - | 37,707 | - | 61,432 | |||
| Property and equipment, net | 54,549 | 52,200 | |||||
| Right-of-use assets, net | 68,585 | 46,731 | |||||
| Intangible assets, net | 37,259 | 37,590 | |||||
| Goodwill | 1,525 | 1,525 | |||||
| Deferred tax assets | 1,899 | 1,039 | |||||
| Other assets | 2,107 | 6,476 | |||||
| Total assets | - | 203,631 | - | 206,993 | |||
| Liabilities and shareholders' equity | |||||||
| Current liabilities | |||||||
| Accounts payable | - | 5,343 | - | 6,332 | |||
| Accrued expenses | 9,852 | 8,423 | |||||
| Income taxes payable | - | 1,003 | |||||
| Derivative liabilities | 1,616 | 2,148 | |||||
| Short term provision liability | - | 4,957 | |||||
| Current portion of notes payable | 1,983 | 755 | |||||
| Lease obligations - current portion | 5,572 | 4,751 | |||||
| Total current liabilities | - | 24,366 | - | 28,369 | |||
| Long-term liabilities | |||||||
| Notes payable, net of current portion and financing costs | 70,202 | 68,775 | |||||
| Lease liabilities, net of current portion | 70,806 | 51,727 | |||||
| Deferred tax liability | 4,708 | 4,817 | |||||
| Uncertain tax position | 55,994 | 43,314 | |||||
| Long term provision liability | 7,414 | 9,044 | |||||
| Convertible notes, net | 7,258 | 6,482 | |||||
| Other long-term liabilities | 3,447 | 3,447 | |||||
| Total long-term liabilities | - | 219,829 | - | 187,606 | |||
| Total liabilities | - | 244,195 | - | 215,975 | |||
| Shareholders' equity | |||||||
| Share capital | 206,629 | 206,419 | |||||
| Share-based compensation reserve | 7,492 | 7,275 | |||||
| Equity conversion feature | 7,097 | 7,097 | |||||
| Warrants | 29,634 | 29,634 | |||||
| Accumulated deficit | (290,220 | - | (258,211 | - | |||
| Accumulated other comprehensive loss | (1,196 | - | (1,196 | - | |||
| Total shareholders' equity | - | (40,564 | - | - | (8,982 | - | |
| Total liabilities and shareholders' equity | - | 203,631 | - | 206,993 | |||
| FLUENT CORP. | ||||||||||||
| CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) | ||||||||||||
| For the three and nine months ended September 30, 2025 and 2024 | ||||||||||||
| (USD '000) | ||||||||||||
| For the three months ended | For the nine months ended | |||||||||||
| September 30, 2025 | September 30, 2024 | September 30, 2025 | September 30, 2024 | |||||||||
| Revenue, net of discounts | - | 26,037 | - | 26,147 | - | 79,485 | - | 78,643 | ||||
| Cost of goods sold | 18,008 | 11,859 | 48,503 | 38,315 | ||||||||
| Gross profit before fair value adjustments | 8,029 | 14,288 | 30,982 | 40,328 | ||||||||
| Fair value adjustments on inventory sold | 611 | (2,099 | - | (1,876 | - | (2,259 | - | |||||
| Unrealized gain (loss) on changes in fair value of biological assets | (551 | - | (611 | - | 1,475 | 8,704 | ||||||
| Gross profit | 8,089 | 11,578 | 30,581 | 46,773 | ||||||||
| Expenses | ||||||||||||
| General and administrative | 4,319 | 3,913 | 13,325 | 12,483 | ||||||||
| Sales and marketing | 5,685 | 5,846 | 18,507 | 17,298 | ||||||||
| Depreciation and amortization | 2,005 | 1,737 | 6,184 | 5,247 | ||||||||
| Share-based compensation | (101 | - | 228 | 217 | 419 | |||||||
| Total expenses | 11,908 | 11,724 | 38,233 | 35,447 | ||||||||
| Income (loss) from operations | (3,819 | - | (146 | - | (7,652 | - | 11,326 | |||||
| Other expense (income) | ||||||||||||
| Finance costs, net | 5,535 | 5,154 | 15,606 | 14,700 | ||||||||
| Change in fair value of derivative liability | 144 | (898 | - | (532 | - | (8,292 | - | |||||
| Change in remeasurement of provision liabillity | 67 | - | (4,723 | - | - | |||||||
| Loss on disposal of assets | 343 | - | 519 | 212 | ||||||||
| Loss from termination of a contract | 6 | - | 6 | 5 | ||||||||
| Other expense (income) | 45 | - | 15 | - | ||||||||
| Total other (income) expense | 6,140 | 4,256 | 10,891 | 6,625 | ||||||||
| Income (loss) before income taxes | (9,959 | - | (4,402 | - | (18,543 | - | 4,701 | |||||
| Income tax expense | 3,628 | 7,379 | 13,466 | 19,700 | ||||||||
| Net comprehensive income (loss) | - | (13,587 | - | - | (11,781 | - | - | (32,009 | - | - | (14,999 | - |
| Net loss per share | ||||||||||||
| Basic and diluted - continuing operations | - | (0.02 | - | - | (0.04 | - | - | (0.06 | - | - | (0.05 | - |
| Weighted average number of shares | ||||||||||||
| Basic number of shares | 604,753,362 | 300,522,916 | 517,497,692 | 299,617,665 | ||||||||
| Diluted number of shares | 700,549,856 | 341,807,051 | 697,326,649 | 341,616,139 | ||||||||
| FLUENT CORP. | |||||||
| CONSOLIDATED STATEMENTS OF CASH FLOW | |||||||
| For the nine months ended September 30, 2025 and September 30, 2024 | |||||||
| (USD '000) | |||||||
| For the nine months ended September 30, | |||||||
| 2025 | 2024 | ||||||
| Cash flows provided by operating activities | |||||||
| Net loss | - | (32,009 | - | - | (14,999 | - | |
| Adjustments for non-cash items: | |||||||
| Unrealized gain on changes in fair value of biological assets | (1,475 | - | (8,704 | - | |||
| Realized loss on fair value amounts included in inventory sold | 1,876 | 2,259 | |||||
| Share-based compensation expense | 217 | 419 | |||||
| Depreciation and amortization | 17,853 | 11,366 | |||||
| Accretion and interest expense | 16,118 | 14,680 | |||||
| Loss on disposition of fixed assets | 490 | 212 | |||||
| Gain on remeasurement of provision liability | (4,654 | - | - | ||||
| Loss on lease modification | 2 | - | |||||
| Loss on termination of contract | 6 | - | |||||
| Loss on loan modification | 36 | - | |||||
| Change in fair value of derivative | (532 | - | (8,292 | - | |||
| Uncertain tax position | 12,680 | 38,816 | |||||
| Deferred tax expense | (969 | - | 4,835 | ||||
| Net change in non-cash working capital | |||||||
| Accounts receivable | (440 | - | 164 | ||||
| Biological assets | (16,977 | - | (11,294 | - | |||
| Inventory | 15,986 | 10,944 | |||||
| Prepaid expenses and other current assets | 1,802 | 960 | |||||
| Right of use assets/liabilities | (10,097 | - | (3,520 | - | |||
| Other assets | 4,369 | (466 | - | ||||
| Accounts payable | (2,993 | - | 2,510 | ||||
| Accrued expenses | 709 | (4,354 | - | ||||
| Other long-term liabilities | - | (435 | - | ||||
| Income taxes | (1,003 | - | (18,672 | - | |||
| Net cash provided by operating activities | - | 995 | - | 16,429 | |||
| Cash flows used in investing activities | |||||||
| Purchases of property and equipment | (14,119 | - | (10,543 | - | |||
| Purchase of intangible assets | (318 | - | (1,332 | - | |||
| Net cash used in investing activities | - | (14,437 | - | - | (11,875 | - | |
| Cash flows used in financing activities | |||||||
| Proceeds from issuance of convertible debenture and warrants | 210 | - | |||||
| Proceeds from issuance of convertible debenture and warrants | - | 3,983 | |||||
| Payments of lease obligations | (3,433 | - | (2,126 | - | |||
| Net proceeds from equipment loan | - | 48 | |||||
| Principal and interest repayments of notes payable | (8,329 | - | (8,048 | - | |||
| Net cash used in financing activities | - | (11,552 | - | - | (6,143 | - | |
| Net decrease in cash | (24,994 | - | (1,589 | - | |||
| Cash, beginning of period | 40,106 | 10,521 | |||||
| Cash, end of period | - | 15,112 | - | 8,932 | |||
| FLUENT CORP. | |||||||||||
| EBITDA AND ADJUSTED EBITDA CALCULATION | |||||||||||
| For the three and nine months ended September 30, 2025 and September 30, 2024 | |||||||||||
| (USD '000) | |||||||||||
| Three months ended | |||||||||||
| September 30, 2025 | September 30, 2024 | Variance | |||||||||
| Net loss | - | (13,587 | - | - | (11,781 | - | - | (1,806 | - | ||
| Interest expense | 5,535 | 5,154 | 381 | ||||||||
| Income taxes | 3,628 | 7,379 | (3,751 | - | |||||||
| Depreciation and amortization | 6,105 | 3,801 | 2,304 | ||||||||
| EBITDA | - | 1,681 | - | 4,553 | - | (2,872 | - | ||||
| Three months ended | |||||||||||
| September 30, 2025 | September 30, 2024 | Variance | |||||||||
| EBITDA | - | 1,681 | - | 4,553 | - | (2,872 | - | ||||
| Change in fair value of biological assets | (60 | - | 2,710 | (2,770 | - | ||||||
| Change in fair market value of derivative | 144 | (898 | - | 1,042 | |||||||
| Change in provision liability | 67 | - | 67 | ||||||||
| Professional fees | 132 | 529 | (397 | - | |||||||
| One-time employee costs | 124 | 162 | (38 | - | |||||||
| Share-based compensation | (101 | - | 228 | (329 | - | ||||||
| Loss on disposal of assets | 343 | - | 343 | ||||||||
| Other non-recurring expense | 507 | 243 | 264 | ||||||||
| Adjusted EBITDA | - | 2,837 | - | 7,527 | - | (4,690 | - | ||||
| Nine months ended | |||||||||||
| September 30, 2025 | September 30, 2024 | Variance | |||||||||
| Net loss | - | (32,009 | - | - | (14,999 | - | - | (17,010 | - | ||
| Interest expense | 15,606 | 14,700 | 906 | ||||||||
| Income taxes | 13,466 | 19,700 | (6,234 | - | |||||||
| Depreciation and amortization | 16,177 | 11,274 | 4,903 | ||||||||
| EBITDA | - | 13,240 | - | 30,675 | - | (17,435 | - | ||||
| Nine months ended | |||||||||||
| September 30, 2025 | September 30, 2024 | Variance | |||||||||
| EBITDA | - | 13,240 | - | 30,675 | - | (17,435 | - | ||||
| Change in fair value of biological assets | 401 | (6,445 | - | 6,846 | |||||||
| Change in fair market value of derivative | (532 | - | (8,292 | - | 7,760 | ||||||
| Change in provision liability | (4,723 | - | - | (4,723 | - | ||||||
| Professional fees | 216 | 4,170 | (3,954 | - | |||||||
| One-time employee costs | 302 | 776 | (474 | - | |||||||
| Share-based compensation | 217 | 419 | (202 | - | |||||||
| Loss on disposal of assets | 519 | 212 | 307 | ||||||||
| Other non-recurring expense/(income) | 477 | 486 | (9 | - | |||||||
| Adjusted EBITDA | - | 10,117 | - | 22,001 | - | (11,884 | - | ||||
